Literature DB >> 2735664

Influence of platelet factor 4 on the neutralization of heparin by protamine.

J N Shanberge1, T M Quattrociocchi-Longe.   

Abstract

In vitro, PF4 is comparable to protamine sulfate in the neutralization of heparin, but the complexes formed with heparin are different. Even with an excess of PF4, no large PF4-heparin complexes are formed and none of the complexes are able to activate ATIII, nor do these complexes dissociate on incubation in plasma at 37 degrees C. The action of PF4 and protamine is complementary. However, excess protamine displaces PF4 or prevents its complexing with heparin. When excess protamine is used to neutralize heparin in the presence of PF4, large heparin-protamine complexes are formed incorporating PF4. In contrast to the heparin-protamine complexes formed without PF4, these do not activate ATIII nor do they dissociate on incubation. Since PF4 is liberated during ECB procedures, its contribution to the stability of heparin-protamine complexes in vivo may influence the amount of protamine needed to neutralize heparin as well as affect the reactions which have been reported on injection of protamine after ECB.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2735664     DOI: 10.1111/j.1749-6632.1989.tb22516.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  Anticoagulation therapy advisor: a decision-support system for heparin therapy during ECMO.

Authors:  R L Peverini; M Sale; W D Rhine; L M Fagan; L A Lenert
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1992

2.  Severe thrombotic and bleeding complications in a baby with heterozygous factor V Leiden and acquired von Willebrand disease on ECMO.

Authors:  Ozlem Bilen; Laura Loftis; Jun Teruya
Journal:  J Extra Corpor Technol       Date:  2011-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.